ReviewInternational journal of molecular sciences2024
The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 35 citations in OpenAlex.
- CAR-T Cell Therapy and Gut Microbiota Modulation in Multiple Sclerosis: Emerging Therapeutic Strategies and Current Limitations.Current issues in molecular biology · 2026Review
- Longitudinal Stability of the Gut Microbiota in Relapsing-Remitting Multiple Sclerosis: A Prospective Observational Study.Microorganisms · 2026Article
- Gut Microbiota Resilience and Environmental Stressors: A Hidden Key to Lifespan Optimization?Probiotics and antimicrobial proteins · 2026Review
- Demyelinating Diseases: From Molecular Mechanisms to Therapeutic Strategies-3rd Edition.International journal of molecular sciences · 2026Article
- Immunoprotective and neuroprotective properties of gut microbiome in psoriasis.Journal of translational autoimmunity · 2026Review
- Gut-brain axis in neurology: microbiome as a modifiable risk factor for multiple sclerosis.Annals of medicine and surgery (2012) · 2026Article
- Synergistic Effects of Plant Polysaccharides and Probiotics: A Novel Dietary Approach for Parkinson's Disease Intervention.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Biotechnological Approaches to Probiotics and Postbiotics through the Gut-Brain Axis Modulation.Iranian biomedical journal · 2026Article
- Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.Frontiers in immunology · 2026Review
- The gut virome and regulatory T cell axis in health and systemic disease.Microbiome research reports · 2026Review
- The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions.Frontiers in neurology · 2026Review
- Immune-gut-metabolite Interactions in Multiple Sclerosis: A Mendelian Randomization and Mediation Study.Current neurovascular research · 2026Article
- SCFAs' pleiotropic role in pathogenesis and salutogenesis: mechanisms in exacerbation and regulation of inflammation and fibrosis from gut to host.Journal of medical microbiology · 2026Review
- Honeysuckle-Derived Nanovesicles Regulate Gut Microbiota for the Treatment of Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders.Molecular neurobiology · 2025Review
- The Endocannabinoid-Microbiota-Neuroimmune Super-System: A Unifying Feedback Architecture for Systems Resilience, Collapse Trajectories, and Precision Feedback Medicine.International journal of molecular sciences · 2025Review
- Microbiota-Derived SCFAs in Multiple Sclerosis: From Immune Priming to Neurodegeneration.Molecular neurobiology · 2025Review
- Hyperbaric oxygen treatment mitigates gut dysbiosis of mice with spinal cord injury.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Linking Nutrients to Multiple Sclerosis Pathogenesis: Biological Evidence and Clinical Implications.Nutrients · 2025Review
- Multi-target Effects of Short-Chain Fatty Acids for Obesity-Related Asthma: Interventional Potential and Challenges.Clinical reviews in allergy & immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative central nervous system (CNS) disorder, characterized by focal inflammation, demyelination, irreversible axonal loss and neurodegeneration. The proposed mechanism involves auto-reactive T lymphocytes crossing the blood-brain barrier (BBB), contributing to inflammation and demyelination. Pro-inflammatory Th1 and Th17 lymphocytes are pivotal in MS pathogenesis, highlighting an imbalanced interaction with regulatory T cells. Dysbiosis in the gut microbiota, characterized by microbial imbalance is implicated in systemic inflammation, yet its exact role in MS remains elusive. Short-chain fatty acids (SCFAs), including valerate, butyrate, propionate, and acetate, produced through dietary fiber fermentation by the gut microbiota, modulate inflammation and immune responses. Particularly, butyrate and propionate exhibit pronounced anti-inflammatory effects in both the gut and CNS. These SCFAs influence regulatory T lymphocyte expression and BBB permeability. This review discusses the potential therapeutic implications of SCFA in MS, highlighting their ability to modulate the gut-brain axis and restore immune balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.